论文部分内容阅读
目前,估计急性白血病人抗白血病疗效唯一可靠的技术是作连续骨髓穿刺或活检。但骨髓穿刺或活检给病人带来痛苦,并非完全没有危险性,且仅能反映整个骨髓中所穿刺的那小部分区域,更不能反映白血病髓外浸润的情况。以血清与尿溶菌酶、血清铜、尿聚胺及尿癌肿相关糖蛋白的测定来估计化疗反应也不够理想或尚处于研究阶段。芳基硫酸酯酶 A和 B(AS-A 和 AS-B)是可溶性溶酶体酶,由肾脏快速清除。正常情况下,尿中的浓度比血清高得多。AS-A 和 B
Currently, the only reliable technique for assessing the efficacy of anti-leukemia in patients with acute leukemia is continuous bone marrow biopsy or biopsy. However, bone marrow biopsy or biopsy to the patient suffering, not completely without danger, and can only reflect the entire bone marrow puncture that small part of the area, but can not reflect leukemia extramedullary infiltration. To serum and urine lysozyme, serum copper, urine polyamines and urine cancer-related glycoprotein measurement to estimate the chemotherapy response is not ideal or still in the research stage. Arylsulfatase A and B (AS-A and AS-B) are soluble lysosomal enzymes that are rapidly cleared by the kidneys. Under normal circumstances, the urine concentration is much higher than serum. AS-A and B